APPLICATION OF THE CYP3A4 SELECTIVE MECHANISM-BASED INACTIVATOR CYP3CIDE TO DELINEATE CYP3A4 AND CYP3A5 CONTRIBUTIONS TO THE METABOLISM OF CYP3A CLEARED DRUGS

被引：0
|
作者：
Tseng, Elaine [1 ]
Walsky, Robert L. [2 ]
Luzietti, Rick [2 ]
Harris, Jennifer [2 ]
Kosa, Rachel E. [1 ]
Zientek, Michael A. [3 ]
Goosen, Theunis C. [1 ]
Obach, R. Scott [1 ]
机构：
[1] Pfizer Global Res & Dev, Groton, CT USA
[2] AstraZeneca, Waltham, MA USA
[3] Pfizer Global Res & Dev, La Jolla, CA USA
来源：
DRUG METABOLISM REVIEWS | 2014年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [1] Relative Contributions of Cytochrome CYP3A4 Versus CYP3A5 for CYP3A-Cleared Drugs Assessed In Vitro Using a CYP3A4-Selective Inactivator (CYP3cide)
    Tseng, Elaine
    Walsky, Robert L.
    Luzietti, Ricardo A., Jr.
    Harris, Jennifer J.
    Kosa, Rachel E.
    Goosen, Theunis C.
    Zientek, Michael A.
    Obach, R. Scott
    DRUG METABOLISM AND DISPOSITION, 2014, 42 (07) : 1163 - 1173
  • [2] USE OF THE CYP3A4 SELECTIVE INHIBITOR CYP3CIDE IN CYP3A5 GENOTYPED CRYOPRESERVED HUMAN HEPATOCYTES TO EXPLORE THE INDIVIDUAL CONTRIBUTION OF CYP3A4 AND CYP3A5 IN DRUG METABOLISM
    Heyward, Scott
    Schultz, Rachel N. V.
    Dennell, Stephen
    DRUG METABOLISM REVIEWS, 2014, 45 : 135 - 136
  • [3] Selective Mechanism-Based Inactivation of CYP3A4 by CYP3cide (PF-04981517) and Its Utility as an In Vitro Tool for Delineating the Relative Roles of CYP3A4 versus CYP3A5 in the Metabolism of Drugs
    Walsky, Robert L.
    Obach, R. Scott
    Hyland, Ruth
    Kang, Ping
    Zhou, Sue
    West, Michael
    Geoghegan, Kieran F.
    Helal, Christopher J.
    Walker, Gregory S.
    Goosen, Theunis C.
    Zientek, Michael A.
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (09) : 1686 - 1697
  • [4] GENERATION AND EVALUATION OF A RELATIVE ACTIVITY FACTOR FOR CYP3A5 THROUGH MECHANISM-BASED INACTIVATION OF CYP3A4 BY CYP3CIDE
    Weber, Jeffrey M.
    Ring, Barbara J.
    Hutzler, J. Matthew
    DRUG METABOLISM REVIEWS, 2015, 47 : 74 - 74
  • [5] The Relative Contributions of CYP3A4 and CYP3A5 to the Metabolism of Vinorelbine
    Topletz, Ariel R.
    Dennison, Jennifer B.
    Barbuch, Robert J.
    Hadden, Chad E.
    Hall, Stephen D.
    Renbarger, Jamie L.
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (09) : 1651 - 1661
  • [6] Comparison of the CYP3A Selective Inhibitors CYP3cide, Clobetasol, and Azamulin for Their Potential to Distinguish CYP3A7 Activity in the Presence of CYP3A4/5
    Work, Hannah M.
    Kandel, Sylvie E.
    Lampe, Jed N.
    DRUG METABOLISM AND DISPOSITION, 2024, 52 (11) : 1224 - 1233
  • [7] Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
    A. B. Sanchez Spitman
    D. J. A. R. Moes
    H. Gelderblom
    V. O. Dezentje
    J.J. Swen
    H. J. Guchelaar
    European Journal of Clinical Pharmacology, 2017, 73 : 1589 - 1598
  • [8] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil
    Wang, YH
    Jones, DR
    Hall, SD
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (05) : 664 - 671
  • [9] Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
    Spitman, A. B. Sanchez
    Moes, D. J. A. R.
    Gelderblom, H.
    Dezentje, V. O.
    Swen, J. J.
    Guchelaar, H. J.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (12) : 1589 - 1598
  • [10] Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: Differential metabolism by CYP3A4 and CYP3A5
    Cook, CS
    Berry, LM
    Kim, DH
    Burton, EG
    Hribar, JD
    Zhang, LM
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (12) : 1344 - 1351
12345